Eli Lilly Opens San Diego Facility
Alexandria Real Estate Equities is the project’s developer and operator.
Eli Lilly and Co. has opened its newest Lilly Gateway Labs site, in San Diego, the pharma company announced Friday.
Developed by and operated in partnership with Alexandria Real Estate Equities Inc., the facility is on the One Alexandria Square Megacampus in Torrey Pines, Calif.
The LGL facilities, of which this is the fourth in the U.S., are designed as “shared innovation hubs” that are intended to support early-stage biotech companies by providing lab space and opportunities to collaborate with Lilly scientists.
The new 82,514-square-foot San Diego facility features flexibly designed office and wet laboratory space to accommodate up to 15 biotech companies with more than 250 employees in total.
LGL San Diego joins two locations in South San Francisco and one in Boston. The LGL model is also expanding globally, Lilly having recently opened a site in Beijing. Since the first Gateway Labs opened in 2019, Lilly reports, LGL-based companies have raised more than $2 billion in capital and supporting the development of 50-plus therapeutics and platforms now in progress.
READ ALSO: 6 Key Trends Shaping the Life Science Sector
The companies based in Gateway Labs represent a diverse array of therapeutic approaches and disease areas, according to Lilly. The company added that LGL San Diego “has already attracted several early-stage biotechs leveraging next-generation modalities to work on some of the body’s most complex systems and difficult-to-treat diseases.”
Neither Lilly nor Alexandria Real Estate Equities replied to Commercial Property Executive’s request for further information.
Lilly deploying $50 billion in capital
Lilly’s Boston LGL site is at the company’s Seaport Innovation Center, a 12-story, 346,000-square-foot building developed by Alexandria Real Estate Equities Inc., in partnership with National Development, at 15 Necco St. in Boston’s Seaport district. Lilly occupied the space in August of last year, after having preleased the entire building, then still underway, in early 2022.
In other sizable real estate moves, Lilly just a few weeks ago announced plans for a $5 billion manufacturing plant in Richmond, Va., as part of its $50 billion capital deployment plan across the U.S.
The facility is to include more than 200,000 square feet of manufacturing space, in addition to office space and other uses. The plant is expected to be completed within the next five years.
And in May, Lilly announced that it was seeking tax incentives to develop a $5.9 billion biomanufacturing plant in Houston, on a 236-acre site in McCord Development’s Generation Park.
You must be logged in to post a comment.